Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 2020 May 7:ehaa404. doi: 10.1093/eurheartj/ehaa404

TeleCheck-AF for COVID-19

Dominik Linz e1,e2,e3,, Nikki A H A Pluymaekers e1, Jeroen M Hendriks e3,e4, on behalf of the TeleCheck-AF investigators
PMCID: PMC7239110  PMID: 32379309

A European mHealth project to facilitate atrial fibrillation management through teleconsultation during COVID19 

During the coronavirus 2019 (COVID-19) pandemic, traditional face-to-face consultations in atrial fibrillation (AF) outpatient clinics were rapidly transferred into teleconsultations, which were initially conducted without any information on heart rhythm or heart rate of the patients. To guarantee the continuity of comprehensive AF management through teleconsultation during COVID-19, we developed a mobile health (mHealth) intervention at the Maastricht Medical University Centre to support AF teleconsultations: TeleCheck-AF.

TeleCheck-AF incorporates three important components: (i) a structured teleconsultation (‘Tele’); (ii) an app-based on-demand heart rate and rhythm monitoring infrastructure (‘Check’); and (iii) comprehensive AF management (‘AF’). The on-demand heart rate and rhythm monitoring infrastructure is based on a CE-marked mobile phone app (www.fibricheck.com) using photoplethysmography (PPG) technology through the built-in camera allowing semi-continuous heart rate and rhythm monitoring of AF patients prior to and during the teleconsultation.

A secretary acts as case coordinator and calls all patients scheduled for teleconsultations in the following week. The patients are instructed why and how to download the mobile phone app and to measure heart rate and rhythm three times per day and note any symptoms. An mHealth prescription (QR-code) activates the app and links the app to a secured cloud accessible by the treating physician. The submission of the recordings to the cloud stops when the prescription (7 days) expires. This on-demand mHealth approach enables the physicians to use heart rate and rhythm data for treatment decisions and prevents unnecessary data collection which would be associated with continuous long-term rhythm monitoring (e.g. wearables or CIEDs) which need to be managed afterwards. The TeleCheck-AF approach is summarized in Figure 1.

Figure 1.

Figure 1

TeleCheck-AF steps

On 4 April 2020, we launched the TeleCheck-AF project (also featured on the ESC website: bit.ly/34R2F65), and we made the above-described TeleCheck-AF infrastructure available to numerous European centres, free of charge during COVID-19.

In the short term, the primary focus of the project is to maintain AF management while keeping patients out of hospital during COVID-19. Since the launch of the project, 23 European hospitals across nine countries have joined the project (Figure 2).

Figure 2.

Figure 2

By 21 April 2020, 18 centres had started data collection and 402 AF outpatient patients had already been managed by the TeleCheck-AF approach. We are currently developing surveys and plans to allow a detailed retrospective analysis of the safety and impact of the TeleCheck-AF approach on patient care during the COVID-19 pandemic.

We hereby would like to invite other centres to participate in TeleCheck-AF. To allow a quick set-up for centres interested in participating, we have developed a portfolio of resources, including patient instruction material and standard operating procedures to synchronize the interventions in the different centres. Centres can be initiated within 48 h after initial contact.

For more information, visit our website: www.TeleCheck-AF.com and follow #TeleCheckAF on Twitter.

Dominik Linz1–3,*, Nikki A. H. A. Pluymaekers1, and Jeroen M. Hendriks3,4; on behalf of the TeleCheck-AF investigators.

1Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, The Netherlands; 2 Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands; 3Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia; and 4College of Nursing and Health Sciences, Flinders University, Adelaide, Australia.

*Corresponding author. Maastricht UMC, Maastricht Heart & Vascular Center, 6202 AZ Maastricht, The Netherlands. Tel: +31 43 3875093, Email: dominik.linz@mumc.nl

Acknowledgements

Heart Foundation Limburg; Biosense Webster, Get smart about AF; FibriCheck.


Articles from European Heart Journal are provided here courtesy of Oxford University Press

RESOURCES